Courses

Review of Targeted Therapeutic Options for BRAF-Mutated Metastatic Colorectal Cancer, Including Combination Therapies

Review of Targeted Therapeutic Options for BRAF-Mutated Metastatic Colorectal Cancer, Including Combination Therapies

In this module, Benny Johnson, DO, along with Scott Kopetz, MD, PhD, course chair, will analyze targeted therapeutic options for BRAF-mutated metastatic colorectal cancer, with a focus on combination therapies. The faculty will highlight the pathway to precision therapy for BRAFV600E mutant metastatic colorectal cancer (mCRC), debating the clinical implications of recent trial data in an interactive panel format. Upon ...
View Course
Update on Optimal Biomarker and Genomic Testing for Colorectal Cancer, Including BRAF Mutations

Update on Optimal Biomarker and Genomic Testing for Colorectal Cancer, Including BRAF Mutations

In this module, Christopher Lieu, MD, along with Scott Kopetz, MD, PhD, course chair, will first discuss the current landscape of genomic testing for metastatic colorectal cancer (mCRC), highlighting the changes in the last decade. Following, the faculty will analyze testing options, covering topics such as gene sequencing, genomic profiling and liquid biopsy and circulating tumor DNA. To conclude, the ...
View Course
Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and M. Patricia Rivera, will first provide a review of current science in non-small cell lung cancer (NSCLC), including trends in stage distribution of lung cancer. Following, current data for targeted therapies as well as immunotherapies in various ...
View Course
Novel Therapeutic Advances to Improve Outcomes in Patients with Tenosynovial Giant Cell Tumor

Novel Therapeutic Advances to Improve Outcomes in Patients with Tenosynovial Giant Cell Tumor

This continuing medical education series includes three, 30-minute serialized, educational interviews, designed to bring clinicians up to date on novel therapeutic advances to improve outcomes in patients with tenosynovial giant cell tumor (TGCT). Tenosynovial giant cell tumor is a rare tumor that often leads to severe morbidity or functional limitations. TGCT is categorized into two subtypes, localized and diffuse, where ...
View Course
Clinical Trial Analysis of BRAF and Anti-PD-1 Targeted Therapeutic Options for Colorectal Cancer

Clinical Trial Analysis of BRAF and Anti-PD-1 Targeted Therapeutic Options for Colorectal Cancer

In this module, Ryan B. Corcoran, MD PhD, along with Scott Kopetz, MD, PhD, course chair, will highlight current clinical trial data for BRAF and Anti-PD-1 targeted therapeutic options in the colorectal cancer treatment landscape. The expert faculty will provide an in-depth review of novel studies by analyzing study populations, methods and results, as well as providing key takeaways for ...
View Course
Targeted Anti-PD-1-based Therapies and Adverse Event Mitigation to Improve Outcomes in Patients with CRC

Targeted Anti-PD-1-based Therapies and Adverse Event Mitigation to Improve Outcomes in Patients with CRC

In this module, Michael J. Overman, MD, along with Scott Kopetz, MD, PhD, course chair, will review clinical trial data of approved and emerging targeted Anti-PD-1-based therapies for the treatment of patients with colorectal cancer, debating the clinical relevance of each in a discussion-based format. The toxicity spectrum of immune-related adverse events will be covered, along with kinetics. Current treatment ...
View Course
Colorectal Cancer Update: Prevalence, Screening, Biomarker and Genomic Testing, and Therapeutic Targets

Colorectal Cancer Update: Prevalence, Screening, Biomarker and Genomic Testing, and Therapeutic Targets

In this module, Jonathan Loree, MD, MS, along with Scott Kopetz, MD, PhD, course chair, will first provide a brief overview of the history and prevalence of colorectal cancer, as well as best practices for screening. Following, the expert faculty will review the role of clinically relevant biomarkers in metastatic colorectal cancer. Strategies for detecting and managing various prevalent mutations ...
View Course
An Interprofessional Team Approach to Deliver Optimal mCRC Patient Care that Addresses Disparities and Patient Education

An Interprofessional Team Approach to Deliver Optimal mCRC Patient Care that Addresses Disparities and Patient Education

In this module, Jamie Faber, PA-C and Tracy Trevino, BSN, RN, along with Scott Kopetz, MD, PhD, course chair, will highlight the role of the interprofessional team in administering optimal patient education and promoting compliance. Practical recommendations for addressing disparities in patient care will also be provided. Further, the expert faculty will discuss side effect management and best practices for ...
View Course
Clinical Updates for the Optimal Management of Patients with Prostate Cancer

Clinical Updates for the Optimal Management of Patients with Prostate Cancer

This CE activity is designed to educate healthcare providers involved in the prevention and management of prostate cancer by presenting the most recent information applicable to clinical practice, with the ultimate goal of improving patient care. Dr. Matthew Smith focuses on recent clinical trials in castration-resistant prostate cancer and the efficacy and safety data outcomes as well as the role ...
View Course
Colorectal Cancer Update: Prevalence, Screening, Biomarker and Genomic Testing, and Therapeutic Targets

Colorectal Cancer Update: Prevalence, Screening, Biomarker and Genomic Testing, and Therapeutic Targets

In this module, Jonathan Loree, MD, MS, along with Scott Kopetz, MD, PhD, course chair, will first provide a brief overview of the history and prevalence of colorectal cancer, as well as best practices for screening. Following, the expert faculty will review the role of clinically relevant biomarkers in metastatic colorectal cancer. Strategies for detecting and managing various prevalent mutations ...
View Course